NIKANG THERAPEUTICS
NiKang Therapeutics is an early-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Its discovery approach is informed by target structure biology and capitalizes on structure-based drug design enabling a rapid and efficient discovery and development of proprietary drug candidates with the most desirable pharmacological features into clinical studies.
NIKANG THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2017-01-01
Address:
Wilmington, Delaware, United States
Country:
United States
Website Url:
http://www.nikangtx.com
Total Employee:
11+
Status:
Active
Contact:
302 644 5450
Email Addresses:
[email protected]
Total Funding:
250 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Apache Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS GoDaddy ThemePunch Starfield Technologies
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Exuma Biotech
EXUMA Biotech is a clinical-stage biotechnology company that focuses on discovering and developing CAR-T cell products for solid tumors.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Advisors List
Current Employees Featured
Founder
Investors List
EcoR1 Capital
EcoR1 Capital investment in Series C - NiKang Therapeutics
Lilly Asia Ventures
Lilly Asia Ventures investment in Series C - NiKang Therapeutics
Pavilion Capital
Pavilion Capital investment in Series C - NiKang Therapeutics
RA Capital Management
RA Capital Management investment in Series C - NiKang Therapeutics
Perceptive Advisors
Perceptive Advisors investment in Series C - NiKang Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series C - NiKang Therapeutics
PFM Health Sciences
PFM Health Sciences investment in Series C - NiKang Therapeutics
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series C - NiKang Therapeutics
Janus Henderson Investors
Janus Henderson Investors investment in Series C - NiKang Therapeutics
Invus
Invus investment in Series C - NiKang Therapeutics
Official Site Inspections
http://www.nikangtx.com Semrush global rank: 5.57 M Semrush visits lastest month: 1.52 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "NiKang Therapeutics"
Nikang Therapeutics
Oct 24, 2024 · Established in 2017, NiKang Therapeutics® is a clinical-stage biotech company dedicated to developing innovative small molecule drugs. Our research relies on disease …See details»
About NiKang - About us – Nikang Therapeutics
In just a few years, NiKang has become a clinical stage biotech company focused on discovering and developing a pipeline of small molecule medicines for difficult-to-drug oncology targets. Our target selection is driven by deep insights into …See details»
NiKang Therapeutics - Crunchbase Company Profile
NiKang Therapeutics is a biotech company focused on discovering and developing small molecule oncology medicines. View contacts for NiKang Therapeutics to access new leads and connect with decision-makers.See details»
NiKang Therapeutics Inc. - LinkedIn
NiKang Therapeutics, Inc. is a privately-held biotech company focused on developing novel small molecule oncology drug discovery. Their mission is to discover and develop first-in-class,...See details»
NiKang Therapeutics - HBM Partners
NiKang Therapeutics, is an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs.See details»
Careers - Nikang Therapeutics
In partnership with world-class leaders in the industry, we are developing new medicines to fight cancer. Together we are on a mission to conquer scientific challenges to combat cancer. Our …See details»
NiKang Therapeutics Announces Completion of $200 Million …
May 26, 2021 · NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecules oncology medicines to help patients with unmet …See details»
Hansoh Pharma and NiKang Therapeutics Enter into a …
NiKang Therapeutics, headquartered in Wilmington, DE, USA, is an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help …See details»
NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration …
Nov 30, 2021 · NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet …See details»
NiKang Therapeutics Enters into Clinical Trial Collaboration and …
Dec 8, 2023 · NiKang Therapeutics is a clinical stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet …See details»
Recommended Stories - Yahoo Finance
WILMINGTON, Del., April 15, 2024 -- (BUSINESS WIRE)--NiKang Therapeutics Inc. ("NiKang") is a clinical stage biotech company focused on developing innovative small molecule oncology …See details»
Ting Jia, Ph.D – Nikang Therapeutics
Dr. Jia is the Founder of Octagon Capital and has served as the firm’s Chief Investment Officer since 2019. Prior to founding Octagon Capital, Dr. Jia served as Managing Director at …See details»
NiKang Therapeutics - VentureRadar
"NiKang Therapeutics is an early stage biotech company focused on discovering and developing innovative small molecule oncology medicines to help patients with unmet medical needs. Our …See details»
NiKang Therapeutics Presents the Discovery and Unique …
Apr 5, 2024 · NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDKs, prolonged pharmacodynamic effects, and a distinct …See details»
NiKang Therapeutics and Pfizer Enter Clinical Trial ... - Nasdaq
Nov 30, 2021 · NiKang Therapeutics Inc., a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs, …See details»
Science & Pipeline - Nikang Therapeutics
NKT3964 is a first-in-class, highly potent and selective, orally bioavailable CDK2 PROTAC degrader, causing prolonged CDK2 pathway inhibition without cyclin E accumulation. It has …See details»
NiKang Therapeutics Announces First Patient Dosed in A Phase …
Nov 15, 2021 · We strive to bring transformative medicines to patients in need. For more information, please visit http://www.nikangtx.com.See details»
Recommended Stories - Yahoo Finance
Sep 9, 2024 · NKT2152 is a potent, selective and orally available small molecule HIF2α inhibitor which binds to HIF2α allosterically and disrupts the HIF2α/HIF1β transcription factor complex, …See details»
NiKang Therapeutics Enters into Clinical Trial Collaboration
Dec 8, 2023 · NiKang Therapeutics Inc. today announced that it has entered into a clinical trial collaboration and supply agreement with F. Hoffmann-La Roche Ltd. (“Roche”) to evaluate …See details»
NiKang Therapeutics® Presents Discovery of NKT3964, a First-in …
Oct 24, 2024 · NiKang Therapeutics® Presents Discovery of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 PROTAC Degrader for Cancer Therapy, at the …See details»